natgillin/translations-raw huggingface dataset:
Packaging unit according to claim 8 or 9, wherein at least part of the enforcing ribs is formed by a label part. 
Jedinica za pakiranje prema zahtjevu 8 ili 9, naznačena time da da je barem dio rebra za ojačanje oblikovan sa dijelom oznake.
Method for packing products, comprising the step of providing a packaging unit according to any of the claims 1-11. 
Postupak za pakiranje proizvoda, naznačen time da sadrži korak osiguravanja jedinice za pakiranje (4, 6, 7 4, 106, 116) prema bilo kojem zahtjevu od 1-11.
Packaging unit according to claim 1 or 2, wherein the label is attached to at least a top surface of the cover part. 
Jedinica za pakiranje prema zahtjevu 1 ili 2, naznačena time da je oznaka pričvršćena barem na gornju površinu poklopca.
The use according to claim 1, wherein the cancer is breast cancer. 
Farmaceutski sastav za upotrebu prema zahtjevu 28, pri čemu je navedena bolest rak dojke.
The use according to claim 1, wherein the cancer is lung cancer. 
Farmaceutski sastav za upotrebu prema zahtjevu 28, pri čemu je navedeni rak rak pluća.
The use according to claim 1, wherein the cancer is head and neck cancer. 
Farmaceutski sastav za upotrebu prema zahtjevu 28, pri čemu je navedeni rak rak glave i vrata.
The antibody or antigen binding fragment for use as claimed in claim 1 or 2, wherein the antibody, or antigen binding fragment comprises a heavy chain variable region having at least 80%, 90%, 95%, 97%, 98% or 99% sequence identity to an amino acid sequence of SEQ ID NO: 7; and a light chain variable region having at least 80%, 90%, 95%, 97%, 98% or 99% sequence identity to an amino acid sequence of SEQ ID NO: 8. 
Izolirano monoklonalno protutijelo ili njegov fragment koji se veže na antigen, prema zahtjevu 1, naznačen/o time, da obuhvaća varijabilno područje jakog lanca, koje ima najmanje 80%, 90%, 95%, 97%, 98% ili 99% identiteta sekvence prema aminokiselinskoj sekvenci od SEQ ID NO:7; i varijabilno područje slabog lanca, koje ima najmanje 80%, 90%, 95%, 97%, 98% ili 99% identiteta sekvence prema aminokiselinskoj sekvenci od SEQ ID NO:8.
The antibody or antigen binding fragment for use as claimed in any one of claims 1 to 4, wherein the antibody or antigen binding fragment comprises a heavy chain having at least 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 9; and a light chain having at least 95%, 97%, 98% or 99% sequence identity to SEQ ID NO: 10. 
Izolirano monoklonalno protutijelo ili njegov fragment koji se veže na antigen, prema bilo kojem od prethodnih zahtjeva, naznačen/o time, da obuhvaća jaki lanac koji ima najmanje 95%, 96%, 97%, 98% ili 99% identiteta sekvence prema SEQ ID NO:9; i slabi lanac koji ima najmanje 95%, 96%, 97%, 98% ili 99% identiteta sekvence prema SEQ ID NO:10.
The antibody or antigen binding fragment for use as claimed in any one of claims 1 to 6, wherein the antibody, or antigen binding fragment inhibits the alternative complement pathway with an IC50 of 20-200 pM as measured by in vitro hemolytic assay when using human C5 depleted serum that is reconstituted with 100 pM human C5. 
Protutijelo prema bilo kojem od zahtjeva 1 do 5, naznačeno time, da posjeduje alternativni komplementni put s IC50 od 20-200 pM, kao što se mjeri pomoću hemolitičkog testiranja in vitro, uporabom iscrpljenog seruma humanog C5, koji se rekonstituira s 100 pM humanog C5.
Use of a compound, which is 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in treatment of graft versus host disease. 
Farmaceutski sastav koji sadrži spoj koji je 3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitril; ili njegovu farmaceutski prihvatljivu sol; i farmaceutski prihvatljiv nosač; pri čemu je navedeni sastav pogodan za oralnu primjenu i za osiguravanje produženog oslobađanja navedenog spoja ili navedene soli.
A compound having a formula selected from the group consisting of: or a pharmaceutically acceptable salt, hydrate or N-oxide thereof, wherein subscript m is an integer of from 0 to 4; 
Spoj, naznačen time, da ima formulu odabranu iz skupine koja se sastoji od: [image] ili njegova farmaceutski prihvatljiva sol, hidrat ili njegov N-oksid, pri čemu je indeks m cijeli broj od 0 do 4;
A compound of claim 1, wherein one of said R3a groups is selected from the group consisting of -Y and -X3-Y, wherein Y is selected from the group consisting of homopiperidinyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, piperidinyl, azetidinyl, pyranyl, tetrahydrofuranyl, piperazinyl, phenyl, thienyl, furanyl, pyridyl, pyrimidinyl, pyrazinyl, pyrrolyl, pyridazinyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, triazolyl, tetrazolyl and oxadiazolyl, which is optionally substituted with from one to three substituents independently selected from the group consisting of halogen, -ORf -NRfRg, -CORf, -CO2Rf, -CONRfRg, -NO2, -Rh and -CN, wherein Rf and Rg are each independently selected from the group consisting of H, C1-8 alkyl, C3-6 cycloalkyl and C1-8 haloalkyl, and each Rh is independently selected from the group consisting of C1-8 alkyl, C3-6 cycloalkyl and C1-8 haloalkyl. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je jedna od navedenih skupina R3a odabrana iz skupine koju čine -Y i -X3-Y, pri čemu je Y odabran iz skupine koju čine homopiperidinil, morfolinil, tiomorfolinil, pirolidinil, piperidinil, azetidinil, tetrahidrofuranil, piranil, piperazinil, fenil, tienil, furanil, piridil, pirimidinil, pirazinil, pirolil, piridizinil, pirazolil, imidazolil, tiazolil, oksazolil, izoksazolil, izotiazolil, triazolil, tetrazolil i oksadiazolil, koji je po izboru supstituiran s jednim do tri supstituenta, koje se neovisno bira između skupine koja se sastoji od halogena, -ORf, -NRfRg, -CORf, -CO2Rf, -CONRfRg, -NO2, -Rh i -CN, pri čemu su Rf i Rgsvaki neovisno odabrani iz skupine koju čine H, C1-8 alkil, C3-6 cikloalkil i C1-8 haloalkil a svaki Rh neovisno je odabran iz skupine koju čine C1-8 alkil, C3-6 cikloalkil i C1-8 haloalkil.
A compound of claim 1, wherein R2a is selected from the group consisting of hydrogen, F, Cl, Br and I. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je R2a odabran iz skupine koju čine vodik, F, Cl, Br i I.
A compound of claim 1 or 17, wherein R2c is selected from the group consisting of F, Cl, Br, CN, NO2, -CO2CH3, -C(O)CH3 and -S(O)2CH3. 
Spoj u skladu s patentnim zahtjevom 1 ili 17, naznačen time, da je R2c odabran iz skupine koju čine F, Cl, Br, CN, NO2, -CO2CH3, -C(O)CH3 i -S(O)2CH3.
A pharmaceutical composition comprising a pharmaceutically acceptable excipient or carrier and a compound of claim 1. 
Farmaceutski pripravak, naznačen time, da sadrži farmaceutski prihvatljivu pomoćnu tvar ili nosač i spoj iz patentnog zahtjeva 1.
A compound of claim 1, wherein R3a is selected from the group consisting of hydrogen, halogen, -ORf, NRfRg, -Rh, -Y, -CN, X3N3, -SO2Rh, X3NRfRg, X3Y, -S(O)3Rf, -C(C=NORf)NRfRg, -NO2, and -NRgC(O)Rf, wherein Y is an optionally substituted group selected from the group consisting of phenyl, pyridyl, pyrimidinyl, oxazolyl, thiazolyl, oxadiazolyl and morpholinyl, and Rh is an optionally substituted group selected from the group consisting of C1-8 alkyl, C1-8 haloalkyl and C3-8 cycloalkyl, and Rf and Rg are each independently an optionally substituted group selected from the group consisting of hydrogen, C1-8 alkyl, C1-8 haloalkyl and C3-8 cycloalkyl. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je R3a odabran iz skupine koja se sastoji od vodika, halogena,, -ORf, NRfRg, -Rh, -Y, -CN, X3N3, -SO2Rh, X3NRfRg, X3Y, -S(O)3Rf, -C(C=NORf)NRfRg, -NO2 i -NRgC(O)Rf, pri čemu je Y je po izboru supstituirana skupina odabrana iz skupine koju čine fenil, piridil, pirimidinil, oksazolil, tiazolil, oksadiazolil i morfolinil, Rh je po izboru supstituirana skupina odabrana iz skupine koju čine C1-8 alkil, C1-8 haloalkil i C3-8 cikloalkil a Rf i Rg su svaki neovisno po izboru supstituirana skupina odabrana iz skupine koju čine vodik, C1-8 alkil, C1-8 haloalkil i C3-8 cikloalkil.
The compound of claim 36, wherein said CCR1-mediated disease or condition is: (a) an inflammatory condition; or (b) an immunoregulatory disorder. 
Spoj u skladu s patentim zahtjevom 36, naznačen time, da je bolest ili stanje posredovano kemokinom CCR1: (a) upalna bolest ili (b) imunoregulatorni poremećaj.
The compound of claim 36, wherein said CCR1-mediated disease or condition is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, transplant rejection, restenosis, dermatitis, eczema, urticaria, vasculitis, inflammatory bowel disease, food allergy, asthma, Alzheimer's disease, Parkinson's disease, psoriasis, lupus erythematosus, osteoarthritis, stroke and encephalomyelitis. 
Spoj u skladu s patentnim zahtjevom 36, naznačen time, da se bolest ili stanje koje je posredovano kemokinom CCR1 odabire iz skupine koju čine reumatoidni artritis, multipla skleroza, odbacivanje transplantata, restenoze, dermatitis, ekcem, urtikarija, vaskulitis, upalne bolesti crijeva, alergija na hranu, astma, Alzheimerova bolest, Parkinsonova bolest, psorijaza, lupus, osteoartritis, udar, restenoza i encefalomijelitis.
The vaccine according to claim 10 for use according to claim 10, wherein said cancer is selected from astrocytoma, pilocytic astrocytoma, dysembryoplastic neuroepithelial tumor, oligodendrogliomas, ependymoma, gliobvlastoma multiforme, mixed gliomas, oligoastrocytomas, medulloblastoma, retinoblastoma, neuroblastoma, germinoma, ter-atoma, gangliogliomas, gangliocytoma, central gangliocytoma, primitive neuroecto-dermal tumors (PNET), medulloblastoma, medulloepithelioma, neuroblastoma, retinoblastoma, ependymoblastoma, tumors of the pineal parenchyma, pineocytoma, pineoblastoma, ependymal cell tumors, choroid plexus tumors, neuroepithelial tumors of uncertain origin, gliomatosis cerebri, astroblastoma, and glioblastoma. 
Cjepivo u skladu s patentnim zahtjevom 10 za upotrebu u skladu s patentnim zahtjevom 10, pri čemu je navedeni karcinom neki od sljedećih: astrocitom, pilocitični astrocitom, disembrioplastičan neuroepitelijalni tumor, oligodendrogliomi, ependimomi, glioblastom multiforme, miješani gliomi, oligoastrocitomi, meduloblastomi, retinoblastomi, neuroblastom, germinom, teratom, gangliogliomi, gangliocitom, centralni gangliocitom, primitivni neuroektodermalni tumori (PNET), meduloblastom, meduloepiteliom, neuroblastom, retinoblastom, ependimoblastom, tumori pinealno parenhima, pineocitom, pineoblastom, tumorni ependimalnih stanica, tumori koroidnog pleksusa, neuroepitelijalni tumori nepoznatog podrijetla, gliomatosis cerebri, astroblastom i glioblastom.
The device according to claim 2, characterized in that the lever (121; 221) for pressing the nail is mounted pivotably in the first support (102; 202), and the pressing force is adjustable by a screw (123; 223) for regulating the pressing of the nail. 
Naprava prema zahtjevu 2, naznačena time što je poluga (121; 221) za pritiskanje nokta montirana zakretno pomično u prvom nosaču (102; 202), i što se sila pritiska može podešavati pomoću vijka (123; 223) za regulaciju pritiska na nokat.
The device according to claim 1, characterized in that the second support (103) comprises two parts joined by screws (105). 
Naprava prema zahtjevu 1, naznačena time što drugi nosač (103) sadrži dva dijela koja su spojena vijcima (105).
The device according to claim 10, characterized in that along the base (201) there are formed protrusions (205) configured to be positioned in grooves (206) of the plate (204). 
Naprava prema zahtjevu 10, naznačena time što su duž osnove (201) izvedeni ispusti (205) prilagođeni za postavljanje u žljebove (206) ploče (204).
The device according to claim 1, characterized in that the means (111, 112; 211, 212) for immobilizing the toe have a form of screws (111, 112; 211, 212) configured to press the toe towards the base. 
Naprava prema zahtjevu 1, naznačena time što sredstva (111, 112; 211, 212) za imobilizaciju nožnog prsta imaju oblik vijaka (111, 112; 211, 212) prilagođenih za pritiskanje nožnog prsta prema osnovi.
The device according to claim 1, characterized in that the means (131, 132; 231, 232) for manipulating at the lateral edges of the nail have a form of hooks (421) configured to lift the lateral edges of the nail. 
Naprava prema zahtjevu 1, naznačena time što sredstva (131, 132; 231, 232) za manipulaciju kod bočnih ivica nokta imaju oblik kuka (421) prilagođenih za podizanje bočnih ivica nokta.
The device according to claim 1, characterized in that the means (131, 132; 231, 232) for manipulating at the lateral edges of the nail have a form of deflecting spatulas (411, 412) configured to deflect aside the flesh of the lateral nail folds 
Naprava prema zahtjevu 1, naznačena time što sredstva (131, 132; 231, 232) za manipulaciju kod bočnih ivica nokta imaju oblik svijajućih lopatica (411, 412) prilagođenih za savijanje u stranu mesa bočnih kožnih nabora oko nokta.
The device according to claim 1, characterized in that the means (141; 242, 242) for manipulating at the front part of the nail have a form of spatulas (401, 402, 403) configured to lift the front edge of the nail. 
Naprava prema zahtjevu 1, naznačena time što sredstva (141; 242, 242) za manipulaciju kod prednjeg dijela nokta imaju oblik lopatica (401, 402, 403) prilagođenih za podizanje prednje ivice nokta.
A represents the heterocycle A1: 
– A predstavlja heterocikl A1:
The compounds according to claims 1-3, characterized in that they are in the form of racemic mixtures, diastereoisomeric mixtures, partially separated mixtures, single optical isomers and/or single diastereoisomers. 
Spojevi u skladu s patentnih zahtjeva 1-3, naznačen time što su u obliku racemičnih smjesa, smjesa dijastereoizomera, djelomično razdvojenih smjesa, pojedinačnih optičkih izomera i/ili pojedinačnih dijastereoizomera.
Use according to any of the claims from 8 to 10 for the control of Plasmopara viticola on vines, Phytophtora infestans and Botrytis Cinerea on tomatoes, Puccinia recondita, Erysiphe graminis, Helminthosporium teres, Septoria nodorum and Fusarium spp. 
Upotreba u skladu s bilo kojim od patentnih zahtjeva od 8 do 10, naznačena time što je namijenjena suzbijanju gljivica Plasmopara viticola kod vinove loze, Phytophtora infestans i Botrytis cinerea kod rajčica, Puccinia rekondita, Erysiphe graminis, Helminthosporium teres, Septoria nodorum i Fusarium spp.
said supply and delivery pressures being greater than the environmental pressure, characterised by the fact that 
navedene dovodne i isporučene tlakove koji su veći od tlaka okoliša, naznačen time da
the closed container (40) altogether hermetically tight sealed to the gaseous fuel, in relation to the fuel passing through the devices contained in it, said fuel being supplied at a higher pressure than the environmental pressure where the system (4) is located, 
zatvoreni spremnik (40) je u potpunosti hermetički čvrsto zatvoren za plinovito gorivo, u odnosu na gorivo koje prolazi kroz uređaje koji se nalaze u njemu, pri čemu se navedeno gorivo isporučuje na veći tlak od okolišnog pritiska gdje je smješten sustav (4),
System (4) according to claim 1, wherein, on at least one of said vents (48), a gas detector device (52) is positioned able to detect the passage of gaseous fuel through said vent (48) and to signal the presence of a leak of fuel. 
Sustav (4) prema zahtjevu 1, naznačen time da je na najmanje jednom od navedenih odušaka (48) smješten uređaj za detektiranje plina (52) koji može detektirati prolaz plinovitog goriva kroz navedeni odušak (48) i koji može signalizirati curenje plina.
System (4) according to claim 1 or 2, wherein, at said vents (48) at least one fan is positioned suitable to improve the extraction of any leaks of gas from the inner volume (44) towards the outside environment and/or suitable to improve the circulation of air inside the inner volume (44). 
Sustav (4) u skladu s patentnim zahtjevom 1 ili 2, naznačen time da je na navedenim otvorima (48) postavljen najmanje jedan ventilator koji je prikladan za poboljšanje vađenja bilo kakvog curenja plina iz unutarnjeg volumena (44) prema vanjskoj okolini i / ili koji je odgovarajući za poboljšanje cirkulacije zraka unutar unutarnjeg volumena (44).
A binary blend of claim 1 for use in the treatment of organ or tissue transplant rejection, graft versus host disease, autoimmune diseases, inflammatory conditions, viral myocarditis, viral diseases caused by viral myocarditis or cancers. 
Binarna smjesa iz patentnog zahtjeva 1 za uporabu u liječenju odbacivanja transplantata organa ili tkiva, bolesti presadka protiv primatelja, autoimunih bolesti, upalnih stanja, virusnog miokarditisa, virusnih bolesti uzrokovanih virusnim miokarditisom ili raka.
the complementary nucleic acids of the nucleic acids as defined in a), b) and c); and 
nukleinske kiseline komplementarne nukleinskim kiselinama definiranih u a), b) i c).
Process for canning seafood raw material into a foodstuffs container which can be hermetically closed, comprising at least the steps of: 
Postupak konzerviranja sirovine za plodove mora u spremnik za prehrambene proizvode kojeg se može hermetički zatvoriti, koji se u najmanju ruku sastoji u koracima:
a portion of said container not filled with foodstuffs, with a gas mixture, hermetically closing said container and heat sterilizing said sealed container, characterized in that said gas mixture introduced in the free volume is made of argon and carbon dioxide, wherein the percentage of argon is equal to at least 30% by volume and the percentage of carbon dioxide is equal to the complementary percentage for 100%. 
dijela navedenog spremnika koji nije napunjen prehrambenim proizvodima, smjesom plinova, – hermetičkog zatvaranjea navedenog spremnika i – topinskog steriliziranja navedenog hermetički zatvorenog spremnika, naznačen time što se navedena smjesa plinova uvedena u slobodni volumen sastoji od argona i ugljičnog dioksida, gdje postotak argona iznosi najmanje 30%, volumno, a postotak ugljičnog dioksida je preostali postotak do 100%.
Process according to claim 1, characterized in that, for the storage in a rigid container, said gas mixture is substantially made of 80% of argon and 20% of carbon dioxide. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se, kod spremanja u čvsti spremnik, navedena smjesa plinova uglavnom sastoji od 80% argona i 20% ugljičnog dioksida.
Process according to claim 1, characterized in that, for the storage in a semi-rigid container, said gas mixture is substantially made of 50% of argon and 50% of carbon dioxide. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se, kod spremanja u polučvsti spremnik, navedena smjesa plinova uglavnom sastoji od 50% argona i 50% ugljičnog dioksida.
Process according to claim 1, characterized in that, for the storage in a flexible container, said gas mixture is substantially made of 30% of argon and 70% of carbon dioxide. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se, kod spremanja u fleksibilni spremnik, navedena smjesa plinova uglavnom sastoji od 30% argona i 70% ugljičnog dioksida.
Process according to any of the preceding claims, characterized in that said step of filling the free volume of said container with a gas mixture is immediately preceded by a step of applying mechanical vacuum in one or more stages. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se neposredno prije navedenog koraka punjenja slobodnog volumena navedenog spremnika smjesom plinova provodi korak mehaničkog vakuumiranja u jednum ili više koraka.
Process according to any of the preceding claims, characterized in that said step of filling said first portion of said container provides for the introduction of other foodstuffs such as vegetables and/or cereals and/or flavouring essences and/or spices, herbs and/or added liquids, such as water, oil or sauces, in addition to the seafood raw material. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeni korak punjenja navedenog prvog dijela navedenog spremnika ostavlja prostor za unos drugih prehrambenih proizvoda, poput povrća i/ili žitarica i/ili aromatičnih tvari i/ili začina, začinskog bilja i/ili dodanih tekućina, poput vode, ulja ili umaka, uz sirovine za plodove mora.
Package of seafood raw material hermetically closed in a foodstuffs container and heat sterilized, wherein said container comprises a first portion filled with at least seafood raw material and a free volume, i.e. 
Pakiranje sirovina za plodove mora u spremnik za prehrambene proizvode koji je hermetički zatvoren i toplinski steriliziran, gdje navedeni spremnik sadrži prvi dio koji je u najmanju ruku ispunjen sirovinama za plodove mora i slobodni volumen, tj.
Package according to claim 8, characterized in that said gas mixture comprises at least argon at about 60 - 85% and carbon dioxide at about 5 - 10% with respect to the free volume. 
Pakiranje u skladu s patentnim zahtjevom 8, naznačen time što navedena smjesa plinova sadrži u najmanju ruku argon od otprilike 60-85% i ugljični dioksid od otprilike 5-10% u odnosu na slobodni volumen.
Package according to claim 8 or 9, characterized in that said portion of container filled with seafood raw material also comprises vegetables and/or cereals and/or flavouring essences and/or spices, herbs and/or added liquids, such as water, oil or sauces. 
Pakiranje u skladu s patentnim zahtjevom 8 ili 9, naznačeno time što navedeni dio of spremnik ispunjen sirovinama za plodove mora također sadrži povrće i/ili žitarice i/ili aromatične tvari i/ili začine, začinsko bilje i/ili dodane tekućine, poput vode, ulja ili umaka.
A fastening element for handling an ingredient container in combination with a lid, according to caim 1, characterised in that subsequently in the horizontal position of the element (5) the ingredient container (4) is squeezed or drained against the bottom section of the lid (10). 
Pričvrsni element za rukovanje sadržajem u spremniku u kombinaciji s poklopcem, prema zahtjevu 1, naznačen time, da se u horizontalnom položaju elementa (5) spremnik sa sadržajem (4) uzastopno istiskuje ili cijedi prema dnu poklopca (10).
A fastening element for handling an ingredient container in combination with a lid, according to claim 1 and 2, characterised in that the cup (6) may have a shape of a plastic mug, glass, cup or vessel. 
Pričvrsni element za rukovanje sadržajem u spremniku u kombinaciji s poklopcem, prema zahtjevu 1 i 2, naznačen time, da posuda (6) može biti u obliku plastičnog bokala, čaše, šalice ili lončića.
hermetically closing said container and heat sterilizing said sealed container, characterized in that said gas mixture introduced in the free volume is made of argon and carbon dioxide, wherein the percentage of argon is equal to at least 30% by volume and the percentage of carbon dioxide is equal to the complementary percentage for 100%. 
– punjenja prvog dijela navedenog spremnika u najmanju ruku sirovinama za plodove mora, – punjenja slobodnog volumena navedenog spremnika, tj. dijela navedenog spremnika koji nije napunjen prehrambenim proizvodima, smjesom plinova, – hermetičkog zatvaranjea navedenog spremnika i – topinskog steriliziranja navedenog hermetički zatvorenog spremnika, naznačen time što se navedena smjesa plinova uvedena u slobodni volumen sastoji od argona i ugljičnog dioksida, gdje postotak argona iznosi najmanje 30%, volumno, a postotak ugljičnog dioksida je preostali postotak do 100%.
The composition according to any of the previous claims, comprising carriers, excipients and/or preservatives for cosmetic use. 
Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da sadrži nosače, pomoćne tvari i/ili konzervanse za korištenje u kozmetičke svrhe.
reacting 9a-hydroxyandrost-4-en-3,17-dione 1 with H2 under hydrogenation conditions to form compound 2 
Reakciju 9a-hidroksiandrost-4-en-3,17-diona 1 s H2 pod hidrogenirajućim uvjetima za dobivanje spoja 2;
reacting compound 2 with acid to form compound 3 
Reakciju spoja 2 s kiselinom za dobivanje spoja 3;